Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) Income from Continuing Operations (2016 - 2025)

Haemonetics has reported Income from Continuing Operations over the past 17 years, most recently at 44775000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 19.35% year-over-year to 44775000.0; the TTM value through Dec 2025 reached 175463000.0, up 34.88%, while the annual FY2025 figure was 167671000.0, 42.63% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 44775000.0 at Haemonetics, up from 38684000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 57973000.0 in Q1 2025 and troughed at 11041000.0 in Q2 2021.
  • A 5-year average of 27525300.0 and a median of 32092500.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 162.61% in 2021 and later soared 546.65% in 2022.
  • Year by year, Income from Continuing Operations stood at 14856000.0 in 2021, then surged by 121.76% to 32944000.0 in 2022, then fell by 5.17% to 31241000.0 in 2023, then rose by 20.09% to 37517000.0 in 2024, then rose by 19.35% to 44775000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for HAE at 44775000.0 in Q4 2025, 38684000.0 in Q3 2025, and 34031000.0 in Q2 2025.